Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Mepact Now Available for Osteosarcoma in the EU: Takeda
February 15, 2010
- SEMINAR
February 15, 2010
- ASKA to Comarket Minclea with Nihon Pharm.
February 15, 2010
- Abbott Aims at Top Share in DES Market in Japan with XIENCE V
February 15, 2010
- Kyowa Kirin to Jointly Distribute KW-2246 with Hisamitsu
February 15, 2010
- RDKK to Launch K-RAS Gene Mutation Test Kit in April
February 15, 2010
- Wakunaga to Build New Plant in California
February 15, 2010
- Nipro to Acquire Home Diagnostics of the US
February 15, 2010
- Generics Priced Higher Than Original Drugs Should Not Be Regarded as Generics: Korosho
February 15, 2010
- HSTTC Mediates Transfer of NCC-Developed Technology to MKI
February 15, 2010
- Only 2% of Current Non-Users to Start Prescribing Rasilez: SSRI
February 15, 2010
- Panel to Review Drugs, Indications That Need Development
February 15, 2010
- 3rd Candidate for JMA President
February 15, 2010
- Takeda to Work Out New Mid-Term Management Plan 1 Year Ahead of Schedule
February 15, 2010
- Daiichi Sankyo Applies for Laninamivir in Japan
February 15, 2010
- JAID Compiles Guidance for Selection of Anti-Flu Drugs
February 15, 2010
- Chugai Aims to Lead Market in 3 Fields: Mr Nagayama
February 15, 2010
- Urief Approved in Europe: Kissei
February 15, 2010
- Smoking Cessation Aids Should Be Covered by Insurance in Young Smokers
February 15, 2010
- US Sales of Prograf Down 17.6% Following Generic Entry
February 15, 2010
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…